v3.25.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member]
Noncontrolling Interests [Member]
Partners' Capital, Beginning Balance at Dec. 31, 2023 $ 244,316 $ 18,573 $ 794,787 $ (19,460) $ (550,938) $ 242,962 $ 1,354
Beginning Balance, Shares at Dec. 31, 2023   166,026,396          
Issuance of shares upon exercise of stock options 534 $ 49 485     534  
Exercised   453,043          
Issuance of shares upon restricted stock units vest, shares   1,480,313          
Issuance of shares upon restricted stock units vest   $ 163 (163)        
Adjustment to additional paid in capital upon debt modification (3,590)   (3,590)     (3,590)  
Adjustment to additional aid in capital upon dissolution of variable interest entity (1,058)   (709)     (709) (349)
Stock-based compensation expense 25,490   25,490     25,490  
Foreign currency translation adjustment, net of tax 1,026     994   994 32
Adjustment to additional paid in capital upon acquiring additional interest in variable interest entity (115)   (115)     (115)  
Net loss (150,049)       (149,269) (149,269) (780)
Ending Balance, Shares at Dec. 31, 2024   167,959,752          
Partners' Capital, Ending Balance at Dec. 31, 2024 116,554 $ 18,785 816,185 (18,466) (700,207) 116,297 257
Issuance of shares upon exercise of stock options 10,439 $ 910 9,529     10,439  
Exercised   7,923,098          
Issuance of shares upon restricted stock units vest, shares   1,069,057          
Issuance of shares upon restricted stock units vest   $ 118 (118)        
Issuance of common shares, net of issuance costs ,Shares   85,660,979          
Issuance of common shares, net of issuance costs ,value 252,846 $ 9,547 243,299     252,846  
Conversion of convertible notes to common stock, Shares   6,185,904          
Conversion of convertible notes to common shares, value $ 30,947 $ 725 30,222     30,947  
Change in par value and equity related transaction costs   $ (38,113) 38,113        
Shares issued in the acquisition of Beckley Psytech, shares 1,546,258 93,580,831          
Shares issued in the acquisition of Beckley Psytech, value $ 455,603 $ 11,555 444,048     455,603  
Shares issued for the settlement of Beckley Psytech's transaction costs 4,036 $ 106 3,930     4,036  
Shares issued for the settlement of Beckley Psytech's transaction costs, Share   900,901          
Stock-based compensation expense 14,213   14,213     14,213  
Foreign currency translation adjustment, net of tax (2,490)     (2,460)   (2,460) (30)
Net loss (660,147)       (660,047) (660,047) (100)
Ending Balance, Shares at Dec. 31, 2025   363,280,522          
Partners' Capital, Ending Balance at Dec. 31, 2025 $ 222,001 $ 3,633 $ 1,599,421 $ (20,926) $ (1,360,254) $ 221,874 $ 127